An interventional study of CPAP in Obstruction Airway, sponsored by University of Utah. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by University of Utah · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Airway Obstruction with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Airway Obstruction · United States.
Among the 40 studies in Airway Obstruction with a site in United States, this one is the 24th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, and was the 39th registered.
148 studies on the registry are indexed under Airway Obstruction; 26 are open to participants now.
Browse Airway Obstruction studies →8 of the 40 studies in Airway Obstruction with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Belgium and 12 more countries
Ages 18–75
WellSpan Health · Sites in United States
Ages 18+ · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Airway Obstruction studies recruiting now, 13 (65%) set no upper age limit and 5 (25%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 52 across 93 interventional studies indexed under Airway Obstruction.
Median enrollment 41 across the 29 interventional studies, 168 across the 11 observational. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 40 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 2 studies filed under Airway Obstruction — fewer than ten, so there is no comparison to draw.
4 of the studies in Airway Obstruction with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT06507670WellSpan HealthPoint of Care Ultrasound for the Detection of Esophageal Food Bolus | 2026-12-31 |
| NCT05881863University of MinnesotaTo Investigate Airway Oxygen Concentrations During Rigid Bronchoscopy Procedures Performed With High Frequency Jet Ventilation | 2026-12-31 |
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Airway Obstruction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test the control and measurements of a new system for airway support in healthy volunteers. The goals of the study are to evaluate how accurately the system can stabilize airway pressure to a desired level, evaluate the accuracy of the system's reported volume of each breath (tidal volume), evaluate the accuracy of the system's reported respiratory rate, evaluate the accuracy of exhaled carbon dioxide monitoring with a standard carbon dioxide monitor when the novel PAP system is used, and evaluate general comfort of the volunteers while using the system.
Sedation procedures involve administering drugs to patients that reduce awareness and pain without complete loss of consciousness. A common side effect of these drugs is partial or complete obstruction of the airway by the airway tissue, inhibiting the flow of oxygen to the lungs. Research has shown that this risk can be effectively reduced by administering PAP therapy during sedation, which involves directing air flow into a tight-fitting mask over the patient's nostrils and/or mouth. However, non-invasive ventilators used for administering PAP therapy are expensive and large, and often not available in areas of the hospital where sedation procedures take place.
The investigators have developed a small and low-cost novel PAP system for use in sedation procedures that controls airway pressure to desired levels (a feature that is generally only available in larger and higher-cost devices), provides estimates for tidal volumes (generally only available with a non-invasive ventilator), provides respiratory rate estimates, and allows for more accurate monitoring of exhaled carbon dioxide with a standard carbon dioxide monitor using a novel approach that to the investigator's knowledge has not been published. The goal of investigator's study is to demonstrate the accuracy of these features in human subjects. The system is much smaller and less expensive than a non-invasive ventilator, provides enhanced respiratory monitoring, and has the potential to be a practical alternative that would make PAP therapy during sedation much more feasible.
The investigator's evaluation will primarily include evaluating the investigator's system's performance against an FDA cleared commercial respiratory monitor to verify accuracy. The investigators anticipate that the investigator's system will automatically adjust oxygen flow to maintain a desired airway pressure even in the presence of variables such as mask leak and patient inhalation flow. The investigators also anticipate that the investigator's system will provide tidal volume estimates within 15% of the respiratory monitor reference measurement, as well as respiratory rate estimates that closely match the respiratory monitor. The investigator's system employs a method that detects when the patient exhales and removes mask pressure during exhalation, and the investigators anticipate that this will result in improved comfort for the patient, as well as improved carbon dioxide monitoring accuracy, since removing flow during exhalation reduces dilution of the expired gas sample that is used for measuring exhaled carbon dioxide levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled healthy volunteers to examine airway pressure support through the investigational device.
Device: CPAP
Airway pressure support through the investigational device
Tidal Volume Accuracy
The mean and standard deviation of the percent difference in tidal volume measurement between our PAP system and the respiratory monitor
Time frame: During the intervention, up to 20 minutes
Respiratory Rate
The average respiratory rate reported by the respiratory monitor and rate reported by the PAP system for each volunteer will be compared. The average difference for each volunteer will be calculated, and a 95% confidence interval will be constructed, with the ideal mean difference being zero with low variance.
Time frame: During the intervention, up to 20 minutes
EtCO2
End-tidal carbon dioxide measurements at 10 cmH2O of mask pressure will be compared between when the system turned off flow during exhalation and when delivering flow throughout the entire breath. We anticipate that end-tidal CO2 levels will read lower when flow is delivered continuously during exhalation because of dilution of the expired gas, and this will be demonstrated by calculating the average difference in end-tidal CO2 between these two approaches.
Time frame: During the intervention, up to 20 minutes
Mask Pressure Control Accuracy
The measured pressure in the mask compared to the set pressure in the 50 milliseconds immediately preceding inhalation will be assessed for evaluating pressure control. Average error will be calculated and a 95% confidence interval will be constructed. We anticipate the error to be less than 1 cmH2O.
Time frame: During the intervention, up to 20 minutes
| Milestone | Intervention: CPAP |
|---|---|
| Started | 13 |
| Completed | 13 |
| Not completed | 0 |
The mean and standard deviation of the percent difference in tidal volume measurement between our PAP system and the respiratory monitor
| Percent difference | CPAP |
|---|---|
| Tidal Volume Accuracy | -1.94 ± 5.44 |
The average respiratory rate reported by the respiratory monitor and rate reported by the PAP system for each volunteer will be compared. The average difference for each volunteer will be calculated, and a 95% confidence interval will be constructed, with the ideal mean difference being zero with low variance.
| difference in breaths/min | CPAP |
|---|---|
| Respiratory Rate | 0.2 (0.09 to 0.31) |
End-tidal carbon dioxide measurements at 10 cmH2O of mask pressure will be compared between when the system turned off flow during exhalation and when delivering flow throughout the entire breath. We anticipate that end-tidal CO2 levels will read lower when flow is delivered continuously during exhalation because of dilution of the expired gas, and this will be demonstrated by calculating the average difference in end-tidal CO2 between these two approaches.
| difference in mmHg | CPAP |
|---|---|
| EtCO2 | 9.2 |
The measured pressure in the mask compared to the set pressure in the 50 milliseconds immediately preceding inhalation will be assessed for evaluating pressure control. Average error will be calculated and a 95% confidence interval will be constructed. We anticipate the error to be less than 1 cmH2O.
| error in cmH2O | CPAP |
|---|---|
| Mask Pressure Control Accuracy | 0.268 (0.039 to 0.497) |
Collected over From enrollment to the end of their participation, up to 30 minutes. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CPAP | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Age, Continuous(Years) | CPAP |
|---|---|
| Mean | 38.9 (24 to 73) |
| Sex: Female, Male(Participants) | CPAP |
|---|---|
| Female | 6 |
| Male | 7 |
| Race (NIH/OMB)(Participants) | CPAP |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 0 |
| White | 6 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | CPAP |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2026 to primary completion in Mar 2026, 0 months.
Results were first posted in Nov 2026, 8 months after primary completion.
Of 36 non-industry interventional studies with no phase under Airway Obstruction, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 37. This study's 0 months is below that.
Counting every sponsor, half of 44 studies reached it within 16 months; a quarter within 3 and three quarters within 37.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jun 2026 → Mar 2026 and completion Jun 2026 → Mar 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.